Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.
LanguageEnglish
Pages989-995
JournalCurrent Opinion in Pharmacology
Volume13
Issue number6
DOIs
Publication statusPublished - 1 Dec 2013

Fingerprint

Oxyntomodulin
Obesity
Hormones
Cholecystokinin
Peptides
Gastrointestinal Hormones
Glucose
Glucagon-Like Peptide 1
Gastric Bypass
Therapeutics
Pharmaceutical Preparations

Cite this

@article{eb506505c1034deb803b035ab2eee3f7,
title = "Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.",
abstract = "The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.",
author = "Nigel Irwin and Peter Flatt",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.coph.2013.09.009",
language = "English",
volume = "13",
pages = "989--995",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier",
number = "6",

}

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. / Irwin, Nigel; Flatt, Peter.

In: Current Opinion in Pharmacology, Vol. 13, No. 6, 01.12.2013, p. 989-995.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.

AU - Irwin, Nigel

AU - Flatt, Peter

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.

AB - The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.

U2 - 10.1016/j.coph.2013.09.009

DO - 10.1016/j.coph.2013.09.009

M3 - Article

VL - 13

SP - 989

EP - 995

JO - Current Opinion in Pharmacology

T2 - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 6

ER -